



NDA 210493/S-003

SUPPLEMENT APPROVAL

Helsinn Healthcare SA
c/o Helsinn Therapeutics Us Inc
Attention: Jason Najdzinowicz
170 Wood Ave South, 5th Floor
Iselin, NJ 08830

Dear Mr. Najdzinowicz:

Please refer to your Supplemental New Drug Application (sNDA) dated and received June 10, 2020, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Akynzeo (fosnetupitant and palonosetron) for Injection.

This "Changes Being Effectuated" supplemental new drug application provides labeling changes to include information about the chemical compatibility of intravenous Akynzeo with intravenous dexamethasone sodium phosphate under the "Dosage and Administration" section of the Prescribing Information.

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the prescribing information) with the addition of any labeling changes in pending "Changes Being Effectuated" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled *SPL Standard for Content of Labeling Technical Qs and As* at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled *SPL Standard for Content of Labeling Technical Qs and As* at

<http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes, and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Grecia C. Edwards, Regulatory Business Process Manager, at (240) 402 - 1773.

Sincerely,

{See appended electronic signature page}

David Lewis, PhD.
Branch Chief, BII
Division of Post-Marketing Activities I
Office of Lifecycle Drug Products
Office of Pharmaceutical Quality
Center for Drug Evaluation and Research

Enclosure:
Content of Labeling



David
Lewis

Digitally signed by David Lewis
Date: 10/27/2020 03:12:06PM
GUID: 508da72000029f287fa31e664741b577